ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

Fred Poordad, Christophe Hézode, Roger Trinh, +14

New England Journal of Medicine

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang, +34

New England Journal of Medicine

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Mark Sulkowski, Joseph J. Eron, David Wyles, +21

JAMA

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee, +19

Hepatology

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Jordan J. Feld, Christophe Moreno, Roger Trinh, +14

Journal of Hepatology

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

Robert S. Brown, Lino Rodrigues, Vladimir Chulanov, +18

Journal of Hepatology

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Jürgen K. Rockstroh, Karine Lacombe, Rolando M. Viani, +19

Clinical Infectious Diseases

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Jacques Reynes, Roger Trinh, Federico Pulido, +8

AIDS Research and Human Retroviruses

Antiretroviral-naive SubjectsWeek 96Human RetrovirusImmunologyClinical Trials +13

MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection

Nancy Reau, P. Kwo, Susan Rhee, +15

Journal of Hepatology

HepatologyKidney TransplantHepatitis CViral HepatitisAntiviral Therapy +8

Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease

Thomas P. Young, Neil Parkin, Eric Stawiski, +3

Antimicrobial Agents and Chemotherapy

ImmunodeficienciesImmunologyLarge DatabaseMutation PatternsAntiviral Drug +14